JPH0747045B2
(ja)
|
1986-10-15 |
1995-05-24 |
株式会社大協精工 |
積層した注射器用滑栓
|
US5171840A
(en)
|
1988-01-22 |
1992-12-15 |
Tadamitsu Kishimoto |
Receptor protein for human B cell stimulatory factor-2
|
US5670373A
(en)
|
1988-01-22 |
1997-09-23 |
Kishimoto; Tadamitsu |
Antibody to human interleukin-6 receptor
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
CA2050918A1
(fr)
|
1990-01-12 |
1991-07-13 |
Raju Kucherlapati |
Production d'anticorps xenogeniques
|
US5016784A
(en)
|
1990-02-15 |
1991-05-21 |
Dexus Research Inc. |
Applicator for highly reactive materials
|
JP3370324B2
(ja)
|
1991-04-25 |
2003-01-27 |
中外製薬株式会社 |
ヒトインターロイキン−6受容体に対する再構成ヒト抗体
|
JP2648897B2
(ja)
|
1991-07-01 |
1997-09-03 |
塩野義製薬株式会社 |
ピリミジン誘導体
|
AU2309692A
(en)
|
1991-07-03 |
1993-02-11 |
Cryolife, Inc. |
Method for stabilization of biomaterials
|
JP3100727B2
(ja)
|
1992-01-23 |
2000-10-23 |
株式会社大協精工 |
変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
|
AU670793B2
(en)
|
1992-04-30 |
1996-08-01 |
Alpha Therapeutic Corporation |
Improved solubilization and stabilization of factor VIII complex
|
CA2147466A1
(fr)
|
1992-10-20 |
1994-04-28 |
Just P. J. Brakenhoff |
Antagonistes du recepteur de l'interleukine-6
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
US5888511A
(en)
|
1993-02-26 |
1999-03-30 |
Advanced Biotherapy Concepts, Inc. |
Treatment of autoimmune diseases, including AIDS
|
US5888510A
(en)
|
1993-07-21 |
1999-03-30 |
Chugai Seiyaku Kabushiki Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
GB9410534D0
(en)
|
1994-05-26 |
1994-07-13 |
Lynxvale Ltd |
Improvements in or relating to growth factor inhibitors
|
CA2203182C
(fr)
|
1994-10-21 |
2009-11-24 |
Asao Katsume |
Remede contre des maladies provoquees par la production d'il-6
|
CN1075387C
(zh)
|
1994-12-29 |
2001-11-28 |
中外制药株式会社 |
含有il-6拮抗剂的抗肿瘤剂的作用增强剂
|
JP4540132B2
(ja)
|
1995-02-13 |
2010-09-08 |
中外製薬株式会社 |
Il−6レセプター抗体を含んでなる筋蛋白分解抑制剤
|
JP3172057B2
(ja)
|
1995-04-05 |
2001-06-04 |
株式会社大協精工 |
ラミネートゴム栓
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
RU2497500C2
(ru)
|
1995-07-27 |
2013-11-10 |
Джинентех, Инк |
Стабильная изотоническая лиофилизированная протеиновая композиция
|
JPH09154588A
(ja)
|
1995-10-07 |
1997-06-17 |
Toagosei Co Ltd |
Vegf結合性ポリペプチド
|
WO1997035620A1
(fr)
|
1996-03-26 |
1997-10-02 |
Eli Lilly And Company |
Formulations de proteine ob
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
WO1997049428A1
(fr)
|
1996-06-27 |
1997-12-31 |
Chugai Seiyaku Kabushiki Kaisha |
Remedes contre les myelomes a utiliser en combinaison avec des agents anti-tumoraux a base d'azote de la moutarde
|
EP0852951A1
(fr)
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
US20070224663A1
(en)
|
1997-03-07 |
2007-09-27 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
US20020187150A1
(en)
|
1997-08-15 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
|
DE69900746T2
(de)
|
1998-01-30 |
2002-08-14 |
Scios Inc |
Gesteuerte verabreichung von peptiden oder proteinen
|
KR100407811B1
(ko)
|
1998-03-17 |
2003-12-01 |
츄가이 세이야꾸 가부시키가이샤 |
인터루킨-6 안타고니스트를 유효성분으로서 함유하는 염증성 장질환의 예방 또는 치료제
|
JP3512349B2
(ja)
|
1999-01-29 |
2004-03-29 |
株式会社大協精工 |
柱状ゴム要素の成形型
|
US7001892B1
(en)
|
1999-06-11 |
2006-02-21 |
Purdue Research Foundation |
Pharmaceutical materials and methods for their preparation and use
|
US7129338B1
(en)
|
1999-07-08 |
2006-10-31 |
Research Association For Biotechnology |
Secretory protein or membrane protein
|
EP1067182A3
(fr)
|
1999-07-08 |
2001-11-21 |
Helix Research Institute |
Proteine secretoire ou proteine de membrane
|
US7029895B2
(en)
|
1999-09-27 |
2006-04-18 |
Millennium Pharmaceuticals, Inc. |
27411, a novel human PGP synthase
|
AU7824900A
(en)
|
1999-10-07 |
2001-04-23 |
Eli Lilly And Company |
Compounds and methods for inhibiting mrp1
|
AU2001241461A1
(en)
|
2000-02-07 |
2001-08-14 |
Millennium Pharmaceuticals, Inc. |
Narc-1, novel subtilase-like homologs
|
US6629949B1
(en)
|
2000-05-08 |
2003-10-07 |
Sterling Medivations, Inc. |
Micro infusion drug delivery device
|
US6659982B2
(en)
|
2000-05-08 |
2003-12-09 |
Sterling Medivations, Inc. |
Micro infusion drug delivery device
|
US7148197B2
(en)
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
EP1317537B1
(fr)
|
2000-09-08 |
2006-12-20 |
Massachusetts Institute Of Technology |
Compositions d'analogues de g-csf et procedes correspondants
|
ATE442862T2
(de)
|
2000-10-12 |
2009-10-15 |
Genentech Inc |
Niederviskose konzentrierte proteinformulierungen
|
CN1259973C
(zh)
|
2000-10-25 |
2006-06-21 |
中外制药株式会社 |
含有il-6拮抗剂作为有效成分的牛皮癣的预防或治疗剂
|
WO2002036165A1
(fr)
|
2000-10-27 |
2002-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
JP2002209975A
(ja)
|
2001-01-19 |
2002-07-30 |
Daikyo Seiko Ltd |
医薬バイアル用ラミネートゴム栓
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
JP4317010B2
(ja)
|
2001-07-25 |
2009-08-19 |
ピーディーエル バイオファーマ,インコーポレイティド |
IgG抗体の安定な凍結乾燥医薬製剤
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
US20060275294A1
(en)
|
2002-08-22 |
2006-12-07 |
Omoigui Osemwota S |
Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
|
US20060078532A1
(en)
|
2004-10-12 |
2006-04-13 |
Omoigui Osemwota S |
Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
|
US20060078533A1
(en)
|
2004-10-12 |
2006-04-13 |
Omoigui Osemwota S |
Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
|
US20060078531A1
(en)
|
2004-10-12 |
2006-04-13 |
Osemwota Sota |
Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
|
US20040101920A1
(en)
|
2002-11-01 |
2004-05-27 |
Czeslaw Radziejewski |
Modification assisted profiling (MAP) methodology
|
WO2004055164A2
(fr)
|
2002-12-13 |
2004-07-01 |
Abgenix, Inc. |
Systeme et methode de stabilisation d'anticorps au moyen d'histidine
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
AU2004229335C1
(en)
|
2003-04-04 |
2010-06-17 |
Genentech, Inc. |
High concentration antibody and protein formulations
|
EP1471152A1
(fr)
|
2003-04-25 |
2004-10-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Mutations du gène humain PCSK9 qui sont associées à la hypercholesterolemia
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
DE10355251A1
(de)
|
2003-11-26 |
2005-06-23 |
Merck Patent Gmbh |
Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
|
US8617550B2
(en)
|
2003-12-19 |
2013-12-31 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment of vasculitis with IL-6 antagonist
|
BRPI0506679A
(pt)
|
2004-02-11 |
2007-05-15 |
Warner Lambert Co |
métodos de tratar osteoartrite com antagonistas de il-6
|
WO2005103081A2
(fr)
|
2004-04-20 |
2005-11-03 |
Genmab A/S |
Anticorps monoclonaux humains diriges contre cd20
|
CA2575838A1
(fr)
|
2004-07-26 |
2006-03-30 |
Biogen Idec Ma Inc. |
Anticorps anti-cd154
|
US20110313024A1
(en)
|
2004-08-20 |
2011-12-22 |
Leonid Beigelman |
RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20070036788A1
(en)
|
2004-09-22 |
2007-02-15 |
Ahmed Sheriff |
Use of a compound for reducing the biological effectiveness of il-6
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
WO2006066088A2
(fr)
|
2004-12-16 |
2006-06-22 |
Genentech, Inc. |
Procedes de traitement de troubles auto-immuns
|
US20060147945A1
(en)
|
2005-01-06 |
2006-07-06 |
Edmonds Brian T |
Novel secreted proteins and their uses
|
WO2007062040A1
(fr)
|
2005-11-22 |
2007-05-31 |
Wyeth |
Preparations a base de proteines hybrides d'immunoglobuline
|
US20080131374A1
(en)
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
ES2366974T3
(es)
|
2006-05-05 |
2011-10-27 |
Isis Pharmaceuticals, Inc. |
Compuestos y procedimientos para modular la expresión de sglt2.
|
JP5825754B2
(ja)
|
2006-05-05 |
2015-12-02 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
Apobの発現を調節するための化合物および方法
|
NZ572666A
(en)
|
2006-05-11 |
2010-11-26 |
Alnylam Pharmaceuticals Inc |
Compositions comprising double stranded rna and methods for inhibiting expression of the pcsk9 gene
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
PT2374818E
(pt)
|
2006-06-02 |
2013-02-13 |
Regeneron Pharma |
Anticorpos com elevada afinidade para o receptor il-6 humano
|
EP3753548A1
(fr)
|
2006-06-16 |
2020-12-23 |
Regeneron Pharmaceuticals, Inc. |
Formulations antagonistes vegf appropriées pour l'administration intravitréenne
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
EP2083860A4
(fr)
|
2006-11-07 |
2010-05-26 |
Merck Sharp & Dohme |
Antagonistes de pcsk9
|
EP2083859A4
(fr)
|
2006-11-07 |
2010-11-24 |
Merck Sharp & Dohme |
Antagonistes de pcsk9
|
US20100040610A1
(en)
|
2006-11-07 |
2010-02-18 |
Ayesha Sitlani |
Antagonists of pcsk9
|
AU2007322265B2
(en)
|
2006-11-07 |
2013-06-20 |
Merck Sharp & Dohme Corp. |
Antagonists of PCSK9
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
MX2009005527A
(es)
|
2006-11-27 |
2009-06-08 |
Isis Pharmaceuticals Inc |
Metodos para el tratamiento de hipercolesterolemia.
|
CN101589143A
(zh)
|
2006-11-27 |
2009-11-25 |
Isis药物公司 |
用于治疗高胆固醇血症的方法
|
JP5100101B2
(ja)
|
2006-12-12 |
2012-12-19 |
キヤノン株式会社 |
画像形成装置
|
AR066042A1
(es)
|
2007-04-13 |
2009-07-22 |
Novartis Ag |
Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
|
US8354102B2
(en)
|
2007-05-15 |
2013-01-15 |
Hoffmann-La Roche Inc. |
Antibodies directed to mGluR7
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
WO2009042765A1
(fr)
|
2007-09-25 |
2009-04-02 |
The Regents Of The University Of California |
Procédés de modulation de la prokinéticine 2 dans le traitement de la réponse au stress et des troubles associés à l'angoisse
|
AU2008304756B8
(en)
|
2007-09-26 |
2015-02-12 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-IL-6 receptor antibody
|
NZ584902A
(en)
|
2007-10-26 |
2012-03-30 |
Schering Corp |
Anti-pcsk9 and methods for treating lipid and cholesterol disorders
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
TWI564021B
(zh)
|
2008-04-11 |
2017-01-01 |
Chugai Pharmaceutical Co Ltd |
Repeated binding of antigen to antigen binding molecules
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
CN102159204B
(zh)
|
2008-09-19 |
2015-04-01 |
辉瑞公司 |
稳定的液体抗体制剂
|
AU2009294680A1
(en)
|
2008-09-19 |
2010-03-25 |
F. Hoffmann-La Roche Ag |
Novel antibody formulation
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
US8748115B2
(en)
|
2008-12-12 |
2014-06-10 |
Merck Sharp & Dohme Corp. |
PCSK9 immunoassay
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
US8357371B2
(en)
|
2008-12-15 |
2013-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to PCSK9
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
US20100216667A1
(en)
|
2008-12-17 |
2010-08-26 |
Meyer Brian K |
Method for determining compatibility of an active pharmaceutical ingredient with materials
|
MX2011009306A
(es)
|
2009-03-06 |
2011-10-13 |
Genentech Inc |
Formulacion con anticuerpo.
|
EA201270019A1
(ru)
|
2009-06-15 |
2012-06-29 |
Элнилэм Фармасьютикалз, Инк. |
Двуцепочечная рнк, включенная в липидный состав и мишенью которой является ген pcsk9
|
CA2764180A1
(fr)
|
2009-06-18 |
2010-12-23 |
Wyeth Llc |
Formulations lyophilisees pour agents immunopharmaceutiques modulaires de petite taille
|
US20110009628A1
(en)
|
2009-07-08 |
2011-01-13 |
Haiyan Liu |
Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
|
EP2456870A1
(fr)
|
2009-07-21 |
2012-05-30 |
Santaris Pharma A/S |
Oligomères anti-sens ciblant pcsk9
|
TWI519685B
(zh)
|
2009-07-22 |
2016-02-01 |
國立大學法人信州大學 |
藍寶石單結晶之製造方法以及藍寶石單結晶之製造裝置
|
WO2011028938A1
(fr)
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Procédés de diminution du taux de cholestérol sérique chez un sujet à l'aide de l'inhibition de pcsk9
|
WO2011037791A1
(fr)
|
2009-09-25 |
2011-03-31 |
Merck Sharp & Dohme Corp. |
Antagonistes de pcsk9
|
EP2483682A1
(fr)
|
2009-10-02 |
2012-08-08 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Combinaison de facteurs de risque cardiovasculaire lp(a) et d'activité de spla2 pour le diagnostic/pronostic d'une maladie/d'un événement cardiovasculaire
|
AU2010313381A1
(en)
|
2009-10-30 |
2012-04-12 |
Merck Sharp & Dohme Corp. |
AX1 and AX189 PCSK9 antagonists and variants
|
WO2011053783A2
(fr)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Antagonistes et variants ax213 et ax132 pcsk9
|
DK3721904T3
(da)
|
2009-11-20 |
2021-11-15 |
Biocon Ltd |
Formuleringer af t1h-antistof
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
JO3274B1
(ar)
|
2009-12-24 |
2018-09-16 |
Regeneron Pharma |
أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
CN102844332B
(zh)
|
2010-03-11 |
2015-08-19 |
瑞纳神经科学公司 |
呈pH依赖性抗原结合的抗体
|
GB201005005D0
(en)
|
2010-03-25 |
2010-05-12 |
Angeletti P Ist Richerche Bio |
New vaccine
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
DE102010024698A1
(de)
|
2010-06-23 |
2011-12-29 |
Eads Deutschland Gmbh |
Verfahren, Vorrichtung und Anordnung zur Entfernung organischer Verschmutzung von Anströmbereichen eines Luftfahrzeugs
|
WO2012044999A2
(fr)
|
2010-10-01 |
2012-04-05 |
Ludwig Institute For Cancer Research Ltd. |
Multimères de protéines réversibles, et leurs procédés de production et d'utilisation
|
PL2624865T3
(pl)
|
2010-10-06 |
2018-11-30 |
Regeneron Pharmaceuticals, Inc. |
Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
|
WO2012054438A1
(fr)
|
2010-10-22 |
2012-04-26 |
Schering Corporation |
Anti-pcsk9
|
EP2638073A4
(fr)
|
2010-11-09 |
2014-05-07 |
Altimab Therapeutics Inc |
Complexes protéiques pour la liaison à un antigène, et leurs procédés d'utilisation
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
US8771696B2
(en)
|
2010-11-23 |
2014-07-08 |
Regeneron Pharmaceuticals, Inc. |
Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
|
WO2012076670A2
(fr)
|
2010-12-10 |
2012-06-14 |
Novartis Ag |
Formulation d'anticorps
|
US20120195910A1
(en)
|
2010-12-22 |
2012-08-02 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
RU2721279C2
(ru)
|
2011-01-28 |
2020-05-18 |
Санофи Байотекнолоджи |
Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов
|
CN103562227B
(zh)
|
2011-02-11 |
2016-12-21 |
诺瓦提斯公司 |
Pcsk9拮抗剂
|
US8440890B1
(en)
|
2011-03-09 |
2013-05-14 |
Pioneer Hi Bred International Inc |
Maize variety inbred PH1D0D
|
US10092706B2
(en)
|
2011-04-20 |
2018-10-09 |
Amgen Inc. |
Autoinjector apparatus
|
AR088782A1
(es)
|
2011-04-29 |
2014-07-10 |
Sanofi Sa |
Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
|
EA032625B1
(ru)
|
2011-05-02 |
2019-06-28 |
Милленниум Фармасьютикалз, Инк. |
КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
US20140004122A1
(en)
|
2011-05-10 |
2014-01-02 |
Amgen Inc. |
Methods for treating or preventing cholesterol related disorders
|
WO2012168491A1
(fr)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Formulations pharmaceutiques d'antagonistes de pcsk9
|
CA2746171C
(fr)
|
2011-07-13 |
2018-11-06 |
William Jani |
Bouchon de fracturation recuperable
|
WO2013008185A1
(fr)
|
2011-07-14 |
2013-01-17 |
Pfizer Inc. |
Traitement avec des anticorps anti-pcsk9
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
EP4252857A3
(fr)
|
2011-09-16 |
2023-12-06 |
Regeneron Pharmaceuticals, Inc. |
Procédés pour réduire les niveaux de lipoprotéine(a) par l'administration d'un inhibiteur de la proprotéine convertase subtilisine kexine 9 (pcsk9)
|
AR087715A1
(es)
|
2011-09-16 |
2014-04-09 |
Lilly Co Eli |
Anticuerpos anti pcsk9 y usos de los mismos
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
US9943594B2
(en)
|
2011-10-11 |
2018-04-17 |
Sanofi Biotechnology |
Methods for the treatment of rheumatoid arthritis
|
CN104159613B
(zh)
|
2012-03-08 |
2016-11-23 |
霍夫曼-拉罗奇有限公司 |
Abeta抗体制剂
|
JP2015515279A
(ja)
|
2012-04-19 |
2015-05-28 |
アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. |
治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
EP3210972A1
(fr)
|
2012-05-25 |
2017-08-30 |
Catabasis Pharmaceuticals, Inc. |
Méthodes de diminution de la proprotéine convertase subtilisine/kexine de type 9 (pcsk9)
|
AR092098A1
(es)
|
2012-08-13 |
2015-03-25 |
Regeneron Pharma |
ANTICUERPOS ANTI-PCSK9 CON CARACTERISTICAS DE UNION DEPENDIENTES DEL pH
|
EP2703009A1
(fr)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Traitements combinés impliquant des anticorps de la PCSK9 humaine
|
EP2703008A1
(fr)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement des groupes de sujets particuliers
|
EP2706070A1
(fr)
|
2012-09-06 |
2014-03-12 |
Sanofi |
Traitements combinés impliquant des anticorps de la PCSK9 humaine
|
RU2538801C2
(ru)
|
2013-02-07 |
2015-01-10 |
Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген" |
ПРИМЕНЕНИЕ ТЕТРАПЕПТИДА Arg-Pro-Gly-Pro В КАЧЕСТВЕ СРЕДСТВА ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
TWI682780B
(zh)
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
CA2914721A1
(fr)
|
2013-06-07 |
2014-12-11 |
Regeneron Pharmaceuticals, Inc. |
Methodes d'inhibition de l'atherosclerose consistant a administrer un inhibiteur de la pcsk9
|
CN115192704A
(zh)
|
2013-10-11 |
2022-10-18 |
赛诺菲生物技术公司 |
Pcsk9抑制剂用于治疗高血脂症的用途
|
US10428157B2
(en)
|
2013-11-12 |
2019-10-01 |
Sanofi Biotechnology |
Dosing regimens for use with PCSK9 inhibitors
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US8945560B1
(en)
*
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
CN106029096A
(zh)
|
2014-02-14 |
2016-10-12 |
瑞泽恩制药公司 |
用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法
|
US20150283236A1
(en)
|
2014-03-17 |
2015-10-08 |
Marie Baccara-Dinet |
Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
|
EP3169362B1
(fr)
|
2014-07-16 |
2020-06-10 |
Sanofi Biotechnology |
Méthodes de traitement de patients présentant un risque cardiovasculaire élevé avec hypercholestérolémie
|
WO2016011256A1
(fr)
|
2014-07-16 |
2016-01-21 |
Sanofi Biotechnology |
Méthodes de traitement de patients présentant une hypercholestérolémie familiale hétérozygote (hefh)
|
EA039310B1
(ru)
|
2015-02-26 |
2022-01-12 |
Санофи Байотекнолоджи |
Способы снижения сердечно-сосудистого риска
|
MX2018002000A
(es)
|
2015-08-18 |
2018-06-19 |
Regeneron Pharma |
Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
|
US10933134B2
(en)
|
2017-03-16 |
2021-03-02 |
Memorial Sloan Kettering Cancer Center |
Combination therapies for treatment of cancer
|
US20190031774A1
(en)
|
2017-06-09 |
2019-01-31 |
Sanofi Biotechnology |
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|
TW202310872A
(zh)
|
2017-06-09 |
2023-03-16 |
法商賽諾菲生物技術公司 |
藉由投予pcsk9抑制劑治療糖尿病患者高血脂症之方法
|
EP3762026A1
(fr)
|
2018-03-06 |
2021-01-13 |
Sanofi Biotechnology |
Utilisation d'un inhibiteur de pcsk9 pour réduire le risque cardiovasculaire
|